Valued at a market cap of $8.2 billion, Henry Schein, Inc. (HSIC) is a leading global provider of healthcare products and services, specializing in serving office-based dental and medical practitioners. Headquartered in Melville, New York, the company operates in 33 countries and territories, employing over 25,000 Team Schein members worldwide.
Companies valued between $2 billion and $10 billion are generally classified as “mid-cap stocks,” and Henry Schein fits this criterion perfectly. With a selection of more than 120,000 branded products and Henry Schein private-label offerings, the company supports more than 1 million customers globally. Additionally, its integrated approach, extensive product offerings, and commitment to ethical business practices position it as a prominent player in the healthcare industry.
However, Henry Schein currently trades 17.9% below its 52-week high of $82.49 recorded on Feb. 5. HSIC’s stock has dropped 6.8% over the past three months, lagging behind the Health Care Select Sector SPDR Fund’s (XLV) 2% rise over the same time frame.
www.barchart.com
Longer term, Henry Schein’s stock has plunged 2.1% on a YTD basis, whereas XLV has decreased marginally. Moreover, shares of HSIC have slumped 4.2% over the past 52 weeks, underperforming the ETF’s 11.5% returns over the same time frame.
The stock has slipped below its 50-day and 200-day moving averages since the end of July, indicating a downtrend.
www.barchart.com
Shares of HSIC fell 7.4% on Aug. 5 after the company reported Q2 2025 earnings. While its adjusted EPS of $1.10 fell short of Wall Street forecasts, revenue of $3.2 billion beat expectations. The earnings miss was driven by sluggish demand for U.S. dental products, as high interest rates, inflation, and lower spending on non-urgent procedures like orthodontics and high-end restoratives weighed on performance.
In the healthcare sector, top rival Cardinal Health, Inc. (CAH), has notably outperformed HSIC stock. Shares of CAH have gained 30.7% on a YTD basis and climbed 40.3% over the past 52 weeks.
Nevertheless, among the 15 analysts covering the HSIC stock, the consensus rating is a “Moderate Buy.” Its mean price target of $73.23 suggests an 8.1% upside potential from current price levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com